Drug intelligence / Profile preview

desipramine + yohimbine

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

A combination of the tricyclic antidepressant (TCA) desipramine and the \u03b12-adrenergic receptor antagonist yohimbine. This combination was investigated as a potential treatment for refractory depression, based on preclinical findings that suggested it might produce faster antidepressant effects than desipramine alone by reducing brain \u03b2-adrenergic receptor function.

Targets

NET (Norepinephrine Transporter)ADRA2A (α2A)

Beyond the preview

Go deeper on desipramine + yohimbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on desipramine + yohimbine.

Explore the full profile